Myriad Genetics Inc. (MYGN)
NASDAQ: MYGN
· Real-Time Price · USD
8.06
0.50 (6.61%)
At close: Oct 03, 2025, 3:59 PM
8.02
-0.50%
After-hours: Oct 03, 2025, 05:37 PM EDT
6.61% (1D)
| Bid | 7.53 |
| Market Cap | 749.94M |
| Revenue (ttm) | 832.9M |
| Net Income (ttm) | -395.2M |
| EPS (ttm) | -4.31 |
| PE Ratio (ttm) | -1.87 |
| Forward PE | 84 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 8.12 |
| Volume | 1,174,006 |
| Avg. Volume (20D) | 1,743,023 |
| Open | 7.60 |
| Previous Close | 7.56 |
| Day's Range | 7.60 - 8.09 |
| 52-Week Range | 3.76 - 27.03 |
| Beta | 1.98 |
| Ex-Dividend Date | n/a |
About MYGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MYGN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MYGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsMyriad Genetics Inc. is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+46.51%
Myriad Genetics shares are trading higher after th...
Unlock content with
Pro Subscription
2 months ago
-2.76%
Myriad Genetics shares are trading higher after the company reported better-than-expected Q2 EPS and sales.
1 month ago · proactiveinvestors.co.uk
ANGLE partners with Myriad Genetics on enhanced patient treatment approach in cancerANGLE PLC (AIM:AGL, OTCQX:ANPCY) has struck a collaboration with Myriad Genetics of the US to explore whether cancer DNA captured from blood can be used alongside existing tumour tissue tests. The liq...
2 months ago · seekingalpha.com
Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue GrowthMyriad Genetics posted Q2 2025 revenue growth of 1% year-over-year, but adjusted for one-time events, growth would have been 5%. Key growth drivers include expanding Hereditary Cancer Testing to unaff...
2 months ago · fool.com
Myriad Genetics (MYGN) Q2 Revenue Up 6%Myriad Genetics (MYGN) Q2 Revenue Up 6%
